# BrightGene

> BrightGene is a VC fund in Beijing backing Biotechnology and Genetics. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 2
- Last investment: Jan 2024
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.bright-gene.com/

BrightGene is a VC fund in Beijing focused on Biotechnology and Genetics. BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.

## Contacts

5 contacts available for BrightGene. Shizune tracks 1 team members at BrightGene. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brightgene?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Genetics | 1 | 50% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 50% |
| United States | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Yuan Lai Zou | Chief Financial Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aoli Biotechnology | Aoli Biotechnology is a biopharmaceutical oral delivery technology provider. Aoli Biotechnology focuses on research into macromolecule oral delivery technology and has developed a number of world-leading excipient technology patents, including soteria and phloral technology. |  | Seed | Jan 29, 2024 |  |
| DNALite Therapeutics | DNALite Therapeutics, Inc. is an early-stage preclinical biotechnology company committed on bringing the next-generation of drugs to the gastrointestinal tract. Currently for some gastrointestinal diseases, such as colorectal cancer and Crohn's disease, complete or partial removal of the colon and/or rectum is the only treatment Our aimis to prevent not manage the progression of theses diseases. We are doing this by harnessing our proprietary technology to carry DNA to cells that drive these diseases. | $1.5M | Seed | Aug 08, 2018 |  |

2 of 2 investments shown.

## Co-investors
- [Berkeley Catalyst Fund (BCF)](https://shizune.co/investors/profile/berkeley-catalyst-fund-bcf) — VC Fund, 1 deal together
- [BIOCHING CAPITAL](https://shizune.co/investors/profile/bioching-capital) — VC Fund, 1 deal together
- Blue Bear Ventures — VC Fund, 1 deal together
- [Highlight Capital](https://shizune.co/investors/profile/highlight-capital-llc) — VC Fund, 1 deal together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 1 deal together
- SVE Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does BrightGene invest in?

BrightGene invests primarily in Biotechnology, Genetics and Biopharma startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BrightGene?

Public channels for BrightGene include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BrightGene?

The team at BrightGene includes Yuan Lai Zou (Chief Financial Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co